

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**金威医疗集团有限公司**

Good Fellow Healthcare Holdings Limited

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 8143)**

## **PROFIT ALERT**

This announcement is made by Good Fellow Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries as the “**Group**”) pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”) and the Inside Information Provisions (as defined under the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders (the “**Shareholders**”) of the Company and potential investors that, based on the latest unaudited consolidated management accounts of the Group for the six months ended 30 September 2024 (the “**Current Period**”) and the information currently available, the Group expects to record an unaudited profit for the Current Period of approximately HK\$7.60 million, as compared to an unaudited loss of approximately HK\$7.41 million for the six months ended 30 September 2023 (the “**Corresponding Period**”). The expected turnaround from loss to profit is primarily attributable to the one-off gain on disposal of subsidiaries of approximately HK\$10.46 million during the Current Period.

Despite the said one-off gain on disposal, the operation of 北京紫荆醫院有限公司 (for transliteration purpose only, Beijing Zijing Hospital Co., Limited<sup>#</sup>) (“**Beijing Zijing**”) (currently known as 北京惠城醫院有限公司) (for transliteration purpose only, Beijing Huicheng Hospital Co., Ltd<sup>#</sup>), a company established in the PRC with limited liability and an indirect non-wholly owned subsidiary of the Company, was suspended since January 2024 and was resumed in April 2024. For further details of the suspension of operation of Beijing Zijing, please refer to the announcements of the Company dated 3 January 2024, 31 January 2024 and 22 April 2024.

Following the re-issue of the Medical Institution Practising Certificate on 16 April 2024, the operation of Beijing Zijing has been fully resumed but the business has not been recovered. The Group is expected to record an unaudited total revenue of approximately HK\$10.44 million for the Current Period as compared with an unaudited total revenue of approximately HK\$26.13 million for the Corresponding Period, representing a decrease of approximately 60.05%. As at the date of this announcement, with an aim to cut costs in its operation of Beijing Zijing, the Company is in the course of adjusting the business strategy in order to enhance overall Group's performance. The Board has adopted certain cost control measures during the Current Period to lower the selling and distribution expenses and administrative expenses, resulting in a decrease of expenses during the Current Period of over 50% as compared with the Corresponding Period. The Company is seeking opportunities to expand its healthcare business to online platforms and other geographic locations, broadening its future revenue stream.

The Company is still finalising the unaudited consolidated financial results of the Group for the Current Period. The information contained in this announcement is only a preliminary assessment by the Board based on the unaudited consolidated management accounts of the Group for the Current Period and the information currently available, which have not been finalised or reviewed by the audit committee or auditor of the Company, may be subject to changes and adjustments.

Shareholders and potential investors are advised to read carefully the interim results announcement of the Company for the Current Period, which is scheduled to be published in November 2024.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Good Fellow Healthcare Holdings Limited**  
**Ng Chi Lung**  
*Chairman and Executive Director*

Hong Kong, 1 November 2024

*As at the date of this announcement, the Board comprises Mr. Ng Chi Lung and Mr. Wu Qiyou as executive Directors; and Ms. Wong Ka Wai, Jeanne, Mr. Lau Tak Kei Arthur and Mr. Lin Yaomin as independent non-executive Directors.*

*This announcement, for which the directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The directors having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the "Latest Listed Company Information" page of the Stock Exchange website at [www.hkexnews.hk](http://www.hkexnews.hk) for at least seven days from the date of publication and on the Company's website at <http://www.gf-healthcare.com>.*